Drug target validation using transcriptome and the CRISPR/Cas9 systems (KAP220131)
To verify the transcriptome-based validity of candidate drugs / compounds derived from comparative analysis of transcripts and published large-scale drug-transcriptome data using next-generation sequencing in various disease models, and establish an efficient verification technique of CRISPR system-based drug action points.